Maya Zigler

Maya Zigler, as the Head of Research at TargImmune Therapeutics AG, plays a pivotal role in shaping the company's innovative approach to cancer immunotherapy and targeted drug delivery. In her current capacity, Maya oversees a dynamic team of 10 scientists dedicated to advancing pre-clinical research, with a focus on solid tumors and oligonucleotide nanoparticle platforms. Her strategic leadership ensures the seamless integration of cutting-edge nanotechnology, pharmacology, and translational research to identify and develop novel therapeutic candidates. Maya's expertise in nanoparticle characterization, in vivo models, and confocal microscopy underpins her ability to optimize drug delivery systems that enhance tumor targeting and immune modulation.

At TargImmune, Maya spearheads key projects aimed at expanding the platform technology, including the design and synthesis of next-generation oligonucleotide therapeutics and nanoparticle formulations. Her deep understanding of non-clinical pharmacology and GLP/Tox regulatory studies ensures that lead compounds progress efficiently through preclinical validation, paving the way for clinical translation. Beyond her scientific acumen, Maya actively manages collaborations with top-tier research institutions and industry partners, fostering innovation and accelerating the development pipeline. Her strong skills in research project management, grant acquisition, and business strategy position her as a vital driver of TargImmune’s mission to deliver transformative cancer treatments. With her combined expertise in scientific research, team leadership, and strategic planning, Maya Zigler continues to elevate TargImmune’s position at the forefront of immuno-oncology and targeted drug delivery technologies.